Mark Quick - Director of Business Development and IR Brad Mason - President and CEO Doug Rice - CFO Mike Finegan - Chief Strategy Officer.

Raj Denhoy - Jefferies Jim Sidoti - Sidoti & Company John Gillings - JMP Securities Imran Zafar - SunTrust.

Hello and welcome to the Orthofix Fourth Quarter 2015 Earnings Conference Call. Today's call is being recorded. I would now like to turn the call over to Mr. Mark Quick, Director of Business Development and Investor Relations. Please go ahead, sir..

Thanks, operator and good afternoon, everyone. I'd like to welcome you to the Orthofix fourth quarter 2015 earnings call. Joining me on the call today is our President and Chief Executive Officer, Brad Mason; Chief Financial Officer, Doug Rice; and Chief Strategy Officer, Mike Finegan.

I will start with our Safe Harbor statements and then pass it over to Brad. During this call we will be making forward-looking statements that involve risks and uncertainties.

All statements other than those of historical fact are forward-looking statements, including any earnings guidance we provide or any statements about our plans, beliefs, strategies, expectations, goals or objectives.

Investors are cautioned not to place undue reliance on such forward-looking statements as there is no assurance that the matters contained in such statements will occur. The forward-looking statements we make on today's call are based on our beliefs and expectations as of today, February 29, 2016.

We do not undertake any obligation to revise or update such forward-looking statements.

Some factors that could cause actual results to be materially different from the forward-looking statements made by us on the call include the risks disclosed under the heading risk factors in our 2015 Form 10-K, as well as additional SEC filings we make in the future. If you need copies, please contact my office at Orthofix in Lewisville, Texas.

In addition, note that on today's call we will refer to certain non-GAAP financial measures in which we exclude certain items from our U.S. GAAP financial results.

We believe that in order to properly understand our short-term and long-term financial trends, investors may wish to review these matters as a supplement to financial performance measures determined in accordance with U.S. GAAP.

Please refer to today's press release announcing our fourth quarter and full year 2015 results available on our website for reconciliation of these non-GAAP performance measures to our U.S. GAAP financial results. At this point, I'll now turn the call over to Brad..

Thanks, Mark and good afternoon, everyone. I will start by giving you an update on our fourth quarter and full year 2015 performance after which Doug will walk you through the financial results that we reported today. I will then follow up with a few thoughts about our expectations for 2016 before opening it up for Q&A.

Overall we exceeded our expectations in the fourth quarter with a very strong finish to a transformational year at Orthofix. Our Q4 results further validate our strategy, momentum and the strength of our businesses.

Additionally, we believe there's significant opportunity to continue to improve our performance going forward which I will discuss in a few minutes. I will give a few financial highlights for the fourth quarter. Net sales grew 7.6% for the quarter on a constant currency basis.

Excluding a benefit from a revenue recognition accounting change in Q3 of 2013, the fourth quarter was our highest quarterly year-over-year growth rate in the last six years. The BioStim Strategic Business Unit or SBU, in particular had another exceptional quarter growing net sales by 13.2% in constant currency over prior year.

The Biologics SBU continued to show consistent topline growth with Q4 increasing net sales by 5.2% in constant currency. The Extremity Fixation business net sales declined by 2.2% in constant currency in the quarter but achieved a modest 1% growth for the full year in the phase of continuing international challenges particularly in Brazil.

And not to be overshadowed by the other SBUs, despite fixation business achieved year-over-year growth in the fourth quarter of 11.9% in constant currency which highlighted a notable turnaround to this business in 2015 as we had expected and communicated at the beginning of the year.

Adjusted EBITDA for the quarter was $19.3 million or 18.4% of net sales which demonstrates the fixed cost absorption and leverage achievable as a result of increasing net sales.

And as previously reported in the fourth quarter of 2015, we initiated a $75 million two year stock repurchase plan that has resulted in stock purchases of approximately 294,000 shares for $11.6 million through December 31, 2015, the repurchase plan we made in effect. I’ll now review a few of our key operating accomplishments for the full year.

As I just mentioned, in our Spine Fixation SBU, we took the necessary steps to successfully turnaround this business both organizationally as well as financially. This included a new leadership team, the expansion of our sales force by over 50%, the acceleration of our new product launches and focus on profitability.

As a measure of that, the Spine Fixation business had the highest quarterly growth rate in almost four years and a positive operating income in Q4 of 2015 for the first time since 2010. As in our Spine Fixation SBU, we continue to invest in our distribution channels in all of our businesses, increasing the size and quality of our footprint.

In 2015, we grew the total number of our U.S. sales people by approximately 20%. We invested in clinical research and our products pipeline to drive organic growth in the years to come.

In 2015, we substantially completed several clinical studies supporting the use of our regenerative products and continue to work on many other preclinical studies supporting all SBUs.

As an example of this, as we reported last week, the Spine Journal recently published online the result of a cellular study that indicate that PEMF therapy may reduce cellular information and degradation associated with disc degeneration in human cells.

PEMF is the core technology in our BioStim products, which we believe may have additional clinical applications beyond bone growth stimulation. We also successfully launched six new products and four line extensions in our Extremity and Spine Fixation businesses in 2015.

And finally, we significantly improved our systems, internal controls and accounting processes.

In addition to remediating our internal control deficiencies, we spent the last 18 months rebuilding the finance and accounting team, installing new commissions and consolidation software, streamlining our chart of accounts worldwide, significantly improving our internal reporting capabilities, and preparing for the reimplementation and upgrade of our Oracle ERP platform, which is scheduled to go live on April 1.

Our 2015 was a very good year overall for Orthofix. Our expectations for 2016 and beyond are to capitalize on our building momentum and continue to drive performance improvement, which I'll discuss after Doug provides you with more detailed financial results.

Doug?.

Thanks, Brad and good afternoon, everyone. I'll start with providing details into our net sales and earnings results and then discuss some of our other financial measures. Total net sales in the quarter were $104.6 million, up 4.3% from the fourth quarter 2014 total net sales of $100.3 million. On a constant currency basis, net sales increased by 7.6%.

Now, I'll talk about each strategic business unit in more detail. Starting with our BioStim SBU, 2015 fourth quarter net sales were $45 million, up 13.2% versus the same period in the prior year. The increase was primarily due to our sales force expansion and an increase in the number of spine procedures.

I would also note that approximately $1.7 million of the growth was a result of one-time program that accelerated backlogged orders.

Turning to our Biologics SBU, 2015 fourth quarter net sales were $16 million, an increase of 5.2% versus the same period in the prior year, primarily driven by our increased number of sales representatives and an increase in the number of spine procedures.

Moving on to our Extremity Fixation SBU, 2015 fourth quarter net sales were $23.9 million, a decrease of 13.5% in comparison to the same period in the prior-year largely due to an unfavorable foreign currency impact of $3.1 million.

On a constant currency basis, the SBU declined 2.2% due primarily to continued international challenges, including weakness in Brazil and the timing of cash collections.

Since we recognize revenue from a large portion of our stocking distributors only on cash collections, we believe the constant currency trailing 12-month revenue growth gives our investors the best measure of the performance of this business. At the end of the fourth quarter, the trailing 12-month growth rate in constant currency was 1%.

And lastly, our Spine Fixation SBUs 2015 fourth quarter net sales were $19.7 million, an increase of 11.5% in comparison to $17.7 million in the same period in the prior year.

On a constant currency basis, the SBU grew 11.9%, the year-over-year growth was driven by the reorganization of the SBU and from additional distributors added in 2015 as a part of our sales force rebuilding and expansion initiatives that Brad mentioned. Now, I will move on to the rest of the P&L.

Fourth quarter gross profit was 83.2%, up $4.4 million from the fourth quarter 2014. Gross margin in the fourth quarter 2015 was 79.5%, up 90 basis points compared to 78.6% in the prior-year period.

The increase in gross profit and gross margin is primarily due to the increased sales mix from our higher-margin regenerative solutions, which were 58% of net sales versus 55% in the prior year period.

Sales and marketing expenses were $44.7 million or 42.7% of net sales in the fourth quarter of 2015, up $2.4 million from $42.4 million or 42.2% of net sales in the fourth quarter of 2014.

The slight increase in these expenses as a percent of net sales was primarily due to the overall increase and the number of sales managers and field-based training personnel as part of the strategy to increase the size and improve the productivity of our sales organizations, as well as sales commission quota over achievement in certain territories.

Net margin, which we define as gross profit minus sales and marketing expenses was $38.5 million or 36.8% of net sales in the fourth quarter of 2015, up $2 million from $36.5 million or 36.4% of net sales in the fourth quarter of 2014. The improvement as a percent of net sales was due to the improvement in gross margins.

General and administrative expenses were $23.7 million or 22.7% of net sales in the fourth quarter of 2015, which was flat on a $1 basis compared to the prior-year period. When adjusting for legal settlements at $4.2 million and Bluecore expenses of $700,000. G&A was $18.8 million or 18% of net sales compared to 21.3% in the prior year.

This improvement reflects a more normalized rate for the next few quarters as we continue to wind down our infrastructure improvement initiatives. Research and development expenses were $7.6 million or 7.2% of net sales in the fourth quarter, which was up from $6.2 million or 6.2% of net sales in the prior year.

Adjusted EBITDA during the fourth quarter was $19.3 million or 18.4% of net sales compared to $16.3 million or 16.3% of net sales in the prior year.

The significant year-over-year increase in adjusted EBITDA is primarily due to increased net income from continuing operations, which was a result of our G&A cost improvement and higher gross margins driven by product mix, partially offset by increased sales and marketing and R&D cost.

Income tax expense for the fourth quarter was $5 million or 71% of income before income taxes as compared to income tax expense of $6.9 million or 373% of income before income taxes in the same period of 2014. Our income tax expense was 128% of income before taxes for the full year 2015 as compared to 130% in 2015.

Our 2015 effective tax rate was inherently volatile, because we had relatively low pretax income and because we had losses in several tax jurisdictions in which we received a little or no-tax benefit. As we increased our pretax income in 2016 and beyond, it will lower our effective tax rate to more normal levels.

Additionally, we believe there are opportunities to drive our long-term tax rate down and are acutely focused on tax planning in order to accomplish this.

Accordingly, we currently believe that our long term normalized tax rate will be 38%, and in order to improve comparability and to eliminate tax rate volatility in our quarterly non-GAAP reporting, we will apply this tax rate to derive adjusted net income prospectively.

For the fourth quarter 2015, we reported net income from continuing operations of $2.1 million or $0.11 per diluted share, and as compared to a net loss from continuing operations of $5.1 million or $0.27 per diluted share for the fourth 2014.

After adjusting for certain expenses, including foreign exchange impacts, strategic investments, restatement and related costs, legal settlements, and the Bluecore infrastructure investments, and net of tax, adjusted net income from continuing operations was $5.3 million or $0.28 per diluted share compared to a net loss of $900,000 or $0.05 per diluted share during the fourth quarter of 2014.

Moving on to the balance sheet highlights, days sales outstanding or DSOs were 55 days at December 31, 2015, down from 56 days at December 31, 2014.

Our inventory turns at the end of Q4, 2015 were 1.5x, which was down from 1.7x at the end of Q4 2014.The decrease in turns was driven by the additional inventory needed for new product launches during the year.

Cash and cash equivalents at the end of 2015, were $63.7 million compared to $71.2 million, which included restricted cash as of December 31, 2014, we continued to have no long term debt on our books.

As Brad, mentioned, as of December 31, 2015 the Company had repurchased approximately 294,000 shares of common stock for $11.6 million under the $75 million share repurchase program. Additionally, the Company has purchased approximately 417,000 shares for $15.9 million for the period from January 1st to February 24, 2016.

In total, since the beginning of the program we’ve repurchased approximately $27.5 million of the $75 million authorized under the program. Cash flow from operations for Q4, 2015 was $17 million compared to $15 million during Q4, 2014.

The increase is primarily reflective of the year-over-year increase and net income of $9.2 million, partially offset by an $8.1 million decrease in cash provided by changes in working capital. The capital expenditures for Q4, 2015 were $6.7 million versus $7 million in the prior year.

For the year, capital expenditures were approximately $28 million which includes Bluecore investments of $16 million.

As I noted on the last call, we anticipate we will incur approximately $6 million of Bluecore expenditures in 2016, and would expect that the mix of these costs will be recognized as approximately 15% operating expenses versus 85% capital expenses.

Free cash flow, to find this cash flow from operations minus capital expenditures was $10.3 million for the quarter compared to $8 million for the prior year period. The year-over-year increase in free cash flow is primarily driven by the operating cash flow increase as well as a slight decrease in capital expenditures.

In 2016, we expect to see our free cash flow generation improve as a result of both our margin expansion strategy and a significant reduction in capital spending relative to 2015. I will now turn it back to Brad..

Thanks, Doug. With 2015 now in the books, this is a great time to reflect on the successful transformation of Orthofix over the last several years. In 2014 we created a vision to become a highly respected orthopedic and spine Company, that delivers exceptional value to our stakeholders.

This vision is beginning to be realized and we are on the right path to fully realize our potential in the next few years, as we focus on business fundamentals including our key 2016 objectives.

Our first objective for 2016 is to grow our sales in each of our businesses faster than the growth in our respective markets by expanding and optimizing our sales force while launching new and innovative products. Specifically, this year we expect to accelerate our new product cadence with 10 new product launches and 7 line extensions.

The most important of these launches will be our next generation bone growth stimulation products at year end, a novel hip fracture system at Extremity Fixation, and in Spine Fixation, our FORZA PTC and PTC PILLAR line of proprietary interbody products, Firebird NXG, a significant upgrade and enhancement to our Pinnacle screw system, and Sentra, a new anterior cervical plate.

Our second key objective is to expand margins through improved operating leverage and SG&A expense reductions. We expect to make good progress in 2016, and this will continue to be a focus area for us in the years ahead.

And lastly, our third objective is to continue to invest in meaningful clinical research particularly for our regenerative technologies to ensure the long term success of the Company.

In 2016 we will continue to work on a variety of clinical studies that are currently in progress both to support the existing products as well as to investigate new indications for the use of our core PEMF technologies. We are also evaluating a plan to initiate new clinical studies throughout the year.

Regarding our expectations for 2016, we expect to achieve net sales at today's FX rates of $407 million to $412 million. This represents a year-over-year growth rate of between 2.7% to 3.9%, and we anticipate growth in each of our SUBs in the year.

We expect that the quarterly distribution of our net sales will generally reflect the same seasonal pattern that we saw in 2015. We expect gross margins in 2016 to be generally flat year-over-year and our percentage of adjusted operating expenses overall to decline marginally for the full year.

More specifically, we expect sales and marketing expenses to be in the range of 44% to 45%, G&A expenses between 16% to 17%, and R&D expenses to be in the 7% to 8% range.

These ranges are averages for the full year and are expected to vary from quarter-to-quarter due to the seasonality of our net sales which will impact our operating income margin disproportionately in the various quarters due to fixed cost absorption and item such as sales and marketing expenses that are more frontloaded in the year.

We expect adjusted EBITDA for the full year to be between $67 million to $70 million. This would produce an increase of 10.4% to 15.3% over 2015. I previously stated that I expected to achieve a higher than 20% adjusted EBITDA percentage in the future.

While we currently don’t expect to achieve that level for the full year in 2016 we expect to achieve this for 2017. We expect for the full year 2016 adjusted earnings per share to be in the range of $1.25 to a $1.35 based on the diluted weighted average of $18.7 million shares.

We expect capital expenditures to be in the range of $15 million to $18 million for the year of which approximately $5 million will be related to finalizing our Bluecore initiatives.

Lastly turning to our 2016 capital deployment strategy, we intend to continue investing in research and development, tuck-in product and technology licenses and acquisitions while executing our stock repurchase plan. Our focus on improving ROIC remains unchanged. With that operator, we can open up the lines for questions..

[Operator Instructions] And we'll take our first question from Raj Denhoy with Jefferies..

Hi, good afternoon. Wonder if I could start a bit on the expenses in the quarter. Most of the leverage in the quarter came on the gross margin line, and your comments around 2016 suggest that you're still aggressively spending on sales and marketing R&D.

So the question is when you think you can start to find more extensive leverage in those expense lines..

Raj, it's Brad, how are you today?.

Good, thanks..

Good.

So we do expect to make some progress in our G&A this year looking for 2% to 3% decline in G&A spending for the year and we may make a slight amount of progress in our sales and marketing but actually on the R&D side we’re actually going up a bit which is what we are trying to do last year we got a little behind in some of our studies and some of our enrollment.

So, I’m a big believer in spending R&D for the future of our company. So you are going to see some in G&A this year we expect and sales and marketing roughly flat and maybe down slightly but that's generally how it’s going to flow out.

The one thing that I would really speak to is the cadence of it for the year with our - I kind of think about our year in three pieces, our first quarter then our second and third quarter which are roughly equal and then our fourth quarter and our first quarter always drops quite a bit over Q4 and then we lose some - we lose a lot of absorption in that Q1.

So, from a percentage basis it's going to be a little bit off from one quarter to next particularly in Q1 and then probably in Q4 will be other way a bit. So, but overall we should see a decline - marginal decline for the year in our operating expenses..

On one point, you noted that the U.S. sales force, I think you noted you increased it by 20% in 2015. That's a big number.

And so I'm curious how you think about the cadence of adding additional salespeople, and at some point I imagine that investment starts to become a pretty good source of leverage, and when do you think that starts to kick in?.

That's a good question Raj. So I think about - I always think about things differentially between the different business unit.

So, Brad Niemann as a President of our BioStim business got a little bit of a head start on expanding the sales force in 2014, a little bit before some of the other businesses as partly why you saw the increase in Q3 and Q4 for our BioStim business is it’s about a year for that - for new sales people who come on board to really contribute to the topline So you are seeing that in our BioStim business, you saw in Q3 and Q4 and then also now you will see a more of that in 2016 for both our biologics, as well as our Spine Fixation business.

We have not added quite as many in the Extremity Fixation business yet, but it will roll out over a period of time. So you saw part of it in 2015, you will see more of it in 2016 and even beyond, because we will continue to expand our sales force, but yes we have got some opportunity coming up..

Okay. And just one last on product question. You did mention Extremity Fixation, you did note that you expected positive growth I guess in all the lines, so you are expecting a turn there.

So couple of questions, it sounds like it is predominantly what you are seeing in international markets, but you have also launched TrueLok Hex in United States, which I think there was quite a bit of excitement about.

So perhaps you could just give us a little bit in terms of what we should expect from Extremity overall as we look into 2016?.

Yes. I think -- if we'd be thinking in the low to mid-single digits for the year, we would be happy if we get into the mid-single digits. We think we have great opportunity with leveraging both our TrueLok Hex as well as our Galaxy product line outside the U.S., but we also have to confirm in Brazil and some other areas of the world. We think the U.S.

will be a good market and a good business for us this year. I think Brazil is we feel it's probably is bottomed out, it's on its way back, but there is still some uncertainty in the business. So we are not as aggressive as we might otherwise be in our forecasting -- in our projections for the year..

Okay, I will leave at there. Thank you..

We will take our next question from Jim Sidoti with Sidoti & Company..

Two questions.

First, what was the legal settlement in the quarter that you took the charge for?.

The legal settlement had to do with going back to 2012 and the issue that we had in Mexico and we settled all that with the U.S. and then Mexico wanted to get their piece of the pie as well.

We actually -- that's an interesting settlement, because if there were some cash involved, but it was also we had the opportunity to work directly with the government down there which was great experience for us.

And we are going to be giving some of that settlement in product and training and we of course for accounting purposes, we book that at the fair value of it, but our cost of -- when we do that when we actually supply those materials and products will be less than that. So we have some opportunity to recover some of that.

But more importantly, it really gives us a great relationship with the Mexican government where we can now deal directly and sell directly to IMSS there, which is great for compliance and it is great for us all around. And I think it's going to be a little bit of a model as to how other companies might work in Mexico.

So we are very excited about that..

All right. And then my second question, you gave an adjusted EPS number for 2016.

Is the primary adjustment going to be the project Bluecore expenses or was there something else there in that $1.25 to $1.35?.

Jim, this is Doug. Now, the adjustments will be the same adjustments that we have used around share-based compensation, FX, any strategic investments that we've traditionally done. But there will be some Bluecore as I mentioned a few minutes ago, we expect some OpEx impacts that we will adjust for there. So those are the primary items..

All right.

And can you give me what you estimate the EPS impact of Bluecore and the share-based adjustments is?.

The OpEx impact of Bluecore will be less than a $1 million for the year. So the EPS impact based on roughly 18.7 million shares. I don't have math in front of me, but that will be around -- could be about $0.05..

And how about for stock-based expense?.

Share-based compensation, we expect to be roughly the same as we had in 2015. So I'll leave at that -- we'd have to do a little math at that, Jim..

All right, thank you..

We will take our next question from John Gillings with JMP Securities..

All right, great. I'm hopping back and forth between a couple calls so I apologize if anybody's asked about this already, but I just wanted to follow up quickly on the options you guys have on eNeura. We're about a year into the 18 month period that you have on that option.

And just wanted to get a sense if you could give us some color on the topic of milestones that you guys will be watching for over the next six months to help decide if you want to pull the trigger on that. Thanks..

Hi John, Mike Finegan here. Thanks for the question. So with eNeura they continue to make very good progress on a number of different fronts. We continue to evaluate their progress. One, notice that they are behind in generating cash flows as they really concentrated on clinical and label expansion planning as opposed to commercial launch.

They have launched commercially, but it's effectively been delayed. And so the cash flows are essentially delayed by a year compared to what our expectations had been.

Given that it's probably on balance less likely that we exercise the option, but we have six more months effectively to go and we will continue to keep actually little bit more than six months. And we will continue to keep a careful eye on it as we go..

Okay, that is helpful. Thanks guys. Appreciate it..

[Operator Instructions] We'll take our next question from Imran Zafar with SunTrust..

Hi, good afternoon everybody. Thanks for taking my questions. I had a couple of topline questions to start.

First, on the Biologics business, you had another nice quarter there and I just wonder how much of that strength is coming from penetration of the spine market versus inroads in foot and ankle? I know you had some nice clinical data published recently. If you can qualitatively talk about where you're seeing that growth come from. Thanks..

Mike - Imran, Mike Finegan here. I would say that we have growth in both parts of the business; however, the growth in spine is better. And even against the reported number that we gave from biologics within that of course we have non-Trinity biologics as well.

And so if you look at the Trinity performance, the Trinity performance is even stronger than the collectively biologic to itself. If you look at that and focus on that it is almost 8% growth for the quarter. So we continue to see good results there and good uptake of the product and a lot of opportunities..

Okay. And then on the BioStim business, obviously another good quarter there. Can you talk about what's been driving that growth in the last couple quarters in terms of competitive gains, better market? What's driving the uplift there? Thanks..

Sure Imran. Yes, it's Brad again. Couple of things. So their growth percentage is little misleading. We are coming up, we have some little bit lower comps, but overall we are very, very happy with that business.

And with -- we are getting some of the growth from just the expansion of spine procedures, we estimate that -- our estimate to be about 3% or so of those procedures. We get – we get a percentage of those procedures and so we're getting some growth from that. We also are benefiting from the addition of the sales force that we put in 2014.

It really started to kick in 2015 in the second half of the year. So we will see some of that continuing going forward. We think overall, that business is still a low to mid-single digit growth business and we have had a couple of good quarters.

We had one of the issues, one of the -- not issues -- one of the things that we did in Q4 that we talked about a few minutes ago was we had a backlog of orders that were being held by some of our sales force so we gave them an incentive to bring those in and reduce that backlog which we did.

That has contributed about $1.7 million or so in the quarter which was about 4% of that 13.2% growth. So overall we are very, very pleased with the business. We are still doing things in the business to streamline the processes so we can move the claims through faster, we get a higher percentage of claims paid, those sorts of things.

And we are really excited about in the fourth quarter, our limited market release of our whole new line of Physio-Stim, Cervical-Stim and Spine Stim products with some really, really good features. So we are very, very happy about that business and expected to do well this year..

Okay. And then lastly, can you just remind us what your topline exposure is to Brazil and Puerto Rico and also what your assumptions are on the 2016 guidance vis-à-vis these two markets? Thanks..

Sure, Brazil has declined over the last four years or so, four or five years. So the exposure is in - between $10 million to $15 million is our top line down there. Now we don’t give it specifically but I will give you kind of a range on it.

And then for Puerto Rico we did approximately $5 million in revenue there last year and this year we got - we are not counting on any because of the financial situation in Puerto Rico that concerns us, so we are not guiding to anything budget for that so Puerto Rico this year.

That’s all upside we do expect to get some, but we don’t know how to quantified is just we’re going to take a little more prudent approach with that. So that’s all upside for us in the numbers – in the guidance that we have been given you so far..

Excellent, that's it from me. Thanks very much..

At this time it appears there are no further questions in the queue. Mr. Mason, I’d like to turn the conference back to you for any additional or closing remarks..

Thank you, Operator and thanks for everybody joining us on the call today. I look forward to updating you on the progress as we go through the year. We’re excited about the year and hopefully I will see some of you down in Orlando later this week. Take care and have a great rest of your day..

That concludes today's presentation. Thank you for your participation..